DNMR Earnings & Forecasts

DNMR (DNMR) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

Quarterly Earnings Surprise Amount

Fiscal Quarter	Date Reported	Actual EPS	Estimated EPS	Surprise %
Q3	Nov 19, 2024	$-0.18	$-8.20	97.8 %
Q2	Aug 8, 2024	$-7.60	$-9.20	17.4 %
Q1	May 7, 2024	$-10.40	$-10.40	0.00 %
Q4	Mar 28, 2024	$-15.60	$-15.20	-2.63 %

Quarterly Revenue (Billions)

Quarterly Revenue Surprise Amount

Fiscal Quarter	Date Reported	Actual Revenue	Estimated Revenue	Surprise %
Q3	Nov 19, 2024	$8.63M	$8.58M	0.58 %
Q2	Aug 8, 2024	$7.63M	$9.27M	-17.7 %
Q1	May 7, 2024	$10.22M	$11.06M	-7.56 %
Q4	Mar 28, 2024	$10.95M	$11.33M	-3.40 %

DNMR Guidance

DNMR (DNMR) last issued guidance on March 20, 2024 for fiscal year 2023. The company guided revenue in the range of $46.7M - $46.7M for the period.

Compared to prior guidance, DNMR raised its revenue forecast from a prior range of $10.9M - $10.9M.

DNMR has issued 3 guidance updates between March 20, 2023 and March 20, 2024. During this period, the company raised its outlook 1 time and lowered it 1 time, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q3 '24	Q2 '24	Q1 '24	Q4 '23
Earnings Per Share (Non-GAAP)
Estimate	$-8.20	$-9.20	$-10.40	$-15.20
Actual	$-0.18	$-7.60	$-10.40	$-15.60
Surprise	+97.8%	+17.4%	0.00%	-2.63%
Revenue
Estimate	$8.6M	$9.3M	$11.1M	$11.3M
Actual	$8.6M	$7.6M	$10.2M	$10.9M
Surprise	+0.58%	-17.7%	-7.56%	-3.40%

Earnings & Guidance News

PRO
Danimer Scientific Q3 EPS $(0.18) Beats $(8.20) Estimate, Sales $8.63M Beat $8.58M Estimate

Danimer Scientific (NYSE:DNMR) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(8.20) by 97.8 percent. This is a 53.85 percent increase over losses of $(0.39) per share from

Benzinga Newsdesk

Earnings Scheduled For November 19, 2024

Benzinga Insights

Preview: Danimer Scientific's Earnings

Benzinga Insights

Earnings Scheduled For November 14, 2024

Benzinga Insights

PRO
Danimer Scientific Names Richard Altice Interim CEO; Preliminary Q3 PHA Revenue Of $6.7M Increased By $0.8M Compared To Q2 2024; Company Maintains Its Forecast That Annualized PHA Revenues Will More Than Triple By The End Of Q2 2025

Current Board Member and Former CEO of NatureWorks to Lead Company While Board Continues Search Process for Permanent CEOCompany Provides Preliminary Third Quarter 2024 PHA ResultsDanimer Scientific, Inc. (NYSE:DNMR)

Benzinga Newsdesk

PRO
Danimer Scientific Forecasts Annualized PHA Revenues To More Than Triple By End Of Q2 2025

Benzinga Newsdesk

DNMR